Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series

• Автори: Hanako Naganawa (Автор), Yoshiki Katada (Автор), Shunsaku Nakagawa (Автор), Keisuke Umemura (Автор), Hiroki Ishimura (Автор), Moto Kajiwara (Автор), Hiroki Endo (Автор), Mitsuhiro Sugimoto (Автор), Yurie Katsube (Автор), Kinuka Kotani (Автор), Saki Ohta (Автор), Daiki Hira (Автор), Masahiro Tsuda (Автор), Yuki Kita (Автор), Takashi Kobayashi (Автор), Tomohiro Terada (Автор)
• Формат: Книга
• Опубліковано: BMC, 2024-07-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract Background Among the oral antivirals used for treating patients with mild-to-moderate novel coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (NMV/RTV) and ensitrelvir (ESV) are inhibitors of cytochrome P450 (CYP) 3A, and therefore, can cause drug-drug interactions with concomitan...